The effect of temperature and hematocrit level of oxygenated cardioplegic solutions on myocardial preservation. 1988

J A Rousou, and R M Engelman, and R H Breyer, and H Otani, and S Lemeshow, and D K Das
Department of Surgery, University of Connecticut School of Medicine, Farmington.

The ideal temperature and hematocrit level of blood cardioplegia has not been clearly established. This study was undertaken (a) to determine the optimal temperature of blood cardioplegia and (b) to study the effect of hematocrit levels in blood cardioplegia. A comparison of myocardial preservation was done among seven groups of animals on the basis of variations in hematocrit levels and temperature of oxygenated cardioplegic solution. The experimental protocol consisted of a 2-hour hypothermic cardioplegic arrest followed by 1 hour of normothermic reperfusion. Group 1 received oxygenated crystalloid cardioplegic solution at 10 degrees C. Groups 2 through 7 received oxygenated blood cardioplegic solution with the following hematocrit values and temperatures: (2) 10%, 10 degrees C; (3) 10%, 20 degrees C; (4) 10%, 30 degrees C; (5) 20%, 10 degrees C; (6) 20%, 20 degrees C; and (7) 20%, 30 degrees C. Parameters studied include coronary blood flow, myocardial oxygen extraction, myocardial oxygen consumption, and myocardial high-energy phosphate levels of adenosine triphosphate and creatine phosphate during control (prearrest), arrest, and reperfusion. Myocardial oxygen consumption at 30 degrees C during arrest was significantly higher than at 10 degrees C and 20 degrees C, which indicates continued aerobic metabolic activity at higher temperature. Myocardial oxygen consumption and the levels of adenosine triphosphate and creatine phosphate during reperfusion were similar in all seven groups. Myocardial oxygen extraction (a measure of metabolic function after ischemia) during initial reperfusion was significantly lower in the 30 degrees C blood group than in the 10 degrees C blood group at either hematocrit level and in the oxygenated crystalloid group, which suggests inferior preservation. The hematocrit level of blood cardioplegia did not affect adenosine triphosphate or myocardial oxygen consumption or extraction. It appears from this study that blood cardioplegia at 10 degrees C and oxygenated crystalloid cardioplegia at 10 degrees C are equally effective. Elevating blood cardioplegia temperature to 30 degrees C, however, reduces the ability of the solution to preserve metabolic function regardless of hematocrit level. Therefore, the level of hypothermia is important in blood cardioplegia, whereas hematocrit level has no detectable impact, and cold oxygenated crystalloid cardioplegia is as effective as hypothermic blood cardioplegia.

UI MeSH Term Description Entries
D008297 Male Males
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D010725 Phosphocreatine An endogenous substance found mainly in skeletal muscle of vertebrates. It has been tried in the treatment of cardiac disorders and has been added to cardioplegic solutions. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1996) Creatine Phosphate,Neoton,Phosphocreatine, Disodium Salt,Phosphorylcreatine,Disodium Salt Phosphocreatine,Phosphate, Creatine
D001769 Blood The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.
D002314 Cardioplegic Solutions Solutions which, upon administration, will temporarily arrest cardiac activity. They are used in the performance of heart surgery. Cardioplegic Solution,Solution, Cardioplegic,Solutions, Cardioplegic
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D005260 Female Females
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts

Related Publications

J A Rousou, and R M Engelman, and R H Breyer, and H Otani, and S Lemeshow, and D K Das
September 1992, The Journal of thoracic and cardiovascular surgery,
J A Rousou, and R M Engelman, and R H Breyer, and H Otani, and S Lemeshow, and D K Das
February 1986, Journal of vascular surgery,
J A Rousou, and R M Engelman, and R H Breyer, and H Otani, and S Lemeshow, and D K Das
February 1988, The Journal of thoracic and cardiovascular surgery,
J A Rousou, and R M Engelman, and R H Breyer, and H Otani, and S Lemeshow, and D K Das
May 1982, The Journal of thoracic and cardiovascular surgery,
J A Rousou, and R M Engelman, and R H Breyer, and H Otani, and S Lemeshow, and D K Das
August 1989, The Journal of thoracic and cardiovascular surgery,
J A Rousou, and R M Engelman, and R H Breyer, and H Otani, and S Lemeshow, and D K Das
June 1992, Nihon Geka Gakkai zasshi,
J A Rousou, and R M Engelman, and R H Breyer, and H Otani, and S Lemeshow, and D K Das
February 2019, Transplantation,
J A Rousou, and R M Engelman, and R H Breyer, and H Otani, and S Lemeshow, and D K Das
August 1982, Circulation,
J A Rousou, and R M Engelman, and R H Breyer, and H Otani, and S Lemeshow, and D K Das
January 1994, Physiological research,
J A Rousou, and R M Engelman, and R H Breyer, and H Otani, and S Lemeshow, and D K Das
January 1994, The Annals of thoracic surgery,
Copied contents to your clipboard!